Mylan (MYL) Shares Bought by CIBC Asset Management Inc
CIBC Asset Management Inc raised its stake in Mylan (NASDAQ:MYL) by 7.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,201 shares of the company’s stock after buying an additional 3,802 shares during the period. CIBC Asset Management Inc’s holdings in Mylan were worth $2,251,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of MYL. Canada Pension Plan Investment Board boosted its stake in shares of Mylan by 99.5% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,217,413 shares of the company’s stock valued at $38,189,000 after purchasing an additional 607,094 shares in the last quarter. FMR LLC boosted its stake in shares of Mylan by 19.8% in the 2nd quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after purchasing an additional 134,258 shares in the last quarter. Toronto Dominion Bank boosted its stake in shares of Mylan by 28.2% in the 3rd quarter. Toronto Dominion Bank now owns 200,017 shares of the company’s stock valued at $6,274,000 after purchasing an additional 43,943 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Mylan by 7.2% in the 3rd quarter. Rhumbline Advisers now owns 791,463 shares of the company’s stock valued at $24,828,000 after purchasing an additional 53,154 shares in the last quarter. Finally, Nomura Holdings Inc. boosted its stake in shares of Mylan by 240.8% in the 2nd quarter. Nomura Holdings Inc. now owns 50,507 shares of the company’s stock valued at $1,961,000 after purchasing an additional 35,686 shares in the last quarter. 75.00% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Mylan (NASDAQ:MYL) opened at $39.28 on Friday. The firm has a market cap of $21,698.85, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 1.09 and a beta of 1.35. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a 12-month low of $29.39 and a 12-month high of $47.82.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.69% of the company’s stock.
MYL has been the subject of a number of research reports. TheStreet raised shares of Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Guggenheim initiated coverage on shares of Mylan in a research note on Tuesday, December 12th. They issued a “buy” rating and a $59.00 price objective for the company. UBS Group set a $46.00 price objective on shares of Mylan and gave the company a “buy” rating in a research note on Monday, December 4th. ValuEngine raised shares of Mylan from a “hold” rating to a “buy” rating in a research note on Friday, December 1st. Finally, BidaskClub raised shares of Mylan from a “hold” rating to a “buy” rating in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. Mylan has an average rating of “Buy” and an average target price of $44.65.
TRADEMARK VIOLATION WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/02/10/mylan-myl-shares-bought-by-cibc-asset-management-inc.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.